Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Shaw, Alice
Item TypeName
Academic Article Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Academic Article Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
Academic Article Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Academic Article ALK in lung cancer: past, present, and future.
Academic Article Targeting anaplastic lymphoma kinase in lung cancer.
Academic Article Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Academic Article ROS1 rearrangements define a unique molecular class of lung cancers.
Academic Article Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Academic Article Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Academic Article Crizotinib.
Academic Article Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Academic Article Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Concept Protein Kinase Inhibitors
Academic Article Hypogonadism related to crizotinib therapy: implications for patient care.
Academic Article ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Academic Article Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Academic Article Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Academic Article Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Academic Article Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.
Academic Article Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Academic Article Ceritinib in ALK-rearranged non-small-cell lung cancer.
Academic Article Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.
Academic Article The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Academic Article Ceritinib in ALK-rearranged non-small-cell lung cancer.
Academic Article ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Academic Article Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Academic Article Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Academic Article Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.
Academic Article Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Academic Article Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Academic Article Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Academic Article Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Academic Article Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article Complex renal cysts associated with crizotinib treatment.
Academic Article Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Academic Article PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Academic Article Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Academic Article Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Academic Article Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Academic Article Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.
Academic Article P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Academic Article Crizotinib Resensitization by Compound Mutation.
Academic Article Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.
Academic Article Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Academic Article Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Academic Article Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?
Academic Article Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
Academic Article Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Academic Article Crizotinib resistance: implications for therapeutic strategies.
Academic Article EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Academic Article Resisting Resistance: Targeted Therapies in Lung Cancer.
Academic Article Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Academic Article Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Academic Article Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Academic Article Targeting ALK: Precision Medicine Takes on Drug Resistance.
Academic Article Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Academic Article J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.
Academic Article Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.
Academic Article Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Academic Article Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Academic Article Fast, Food and Ceritinib in ALK-Positive NSCLC.
Academic Article Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Academic Article ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?
Academic Article Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Academic Article SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Academic Article Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
Academic Article Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Academic Article Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.
Academic Article Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Academic Article Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
Academic Article Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Academic Article Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Academic Article Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
Academic Article Refining precision cancer therapy in ALK-positive NSCLC.
Academic Article Clinical Management of Adverse Events Associated with Lorlatinib.
Academic Article ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Academic Article The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Academic Article Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Academic Article Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Search Criteria
  • Protein Kinase Inhibitors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.